tbuckley/cabot-search huggingface dataset:
Randomized multicenter phase III trial of oxaliplatin plus raltitrexed compared to oxaliplatin plus fluorouracil and leucovorin treatment in recurrent and metastatic colorectal cancer
Authors: J. Wang, J. Li, S. Qin, T. Liu, Z. Ye, L. Zheng, M. Tao, Z. Zhuang, Q. Zhang, N. Xu, Y. Zhang
Journal: Journal of Clinical Oncology (2007)

4102 Purpose: To compare oxaliplatin (L-OHP) plus raltitrexed (RTX) with L-OHP plus fluorouracil and leucovorin (LV/5FU) for patients (pts) with recurrent and metastatic colorectal cancer(CRC). Methods: Eligible pts had to have histologically proven recurrent or metastatic CRC,not having previously received oxaliplatin as palliative chemotherapy,ECOG PS = 2,age:18∼70,and adequate hematological,renal and hepatic function.After written informed consent,pts were randomized to L-OHP:130 mg/m 2 d1 + RTX: 3 mg/m 2 d1 (Arm A) or + LV: 200 mg/m 2 + 5FU:375 mg/m 2 d1–5 (Arm B). Results: Between Jan 2005 and July 2006, 216 pts were enrolled at 15 centers in China.112 pts (mean age: 55.0 (19∼70), M/F: 57/46, PS 0/1/2: 46/53/13) were randomly assigned to A and 102 (mean age: 54.2(22∼70), M/F: 54/46, PS 0/1/2: 44/59/9) to B. 203 pts were eligible for response evaluation (A:103, B:100).The median number of cycles was 4 (1∼6) in A and 3 (1∼6) in B (P=0.1431).The RR was 29.1% (CR:2, PR:28, SD:50 , PD:23) in A and 17.0% (CR:2, PR:15, SD:46 , PD:37) in B (P=0.0437).The disease-control rate was 77.7% in A and 63.0% in B (P=0.0237). After a median follow-up of 10 months (4–16.5),92 pts had had progression of disease (40 in A and 52 in B); 73 deaths had occurred (35 in A and 38 in B), median time to progression was not reached. Following-up is ongoing.The median QoL scores for the two arms were comparable. 214 were included in the safety analyses (A:112, B:102). There was a higher incidence of neutropenia (48.2% verse 29.4%, P=0.005) and transaminase increase (49.1% verse 35.3%, P=0.041) among A. Grade 3 or 4 neutropenia was much common in pts in A than those in B (20.5% verse 4.9% , P=0.001), but was complicated by fever in only 3.6% of cases (4 pts) in A and in 2.9% of cases (3 pts) in B. No pts were dead or infectious due to neutropenia. There were similar rates of grade 3 or 4 transaminase elevation in the two groups. Vomitting and anorexia were much commoner with B. Conclusions: The L-OHP+RTX seems beneficial in recurrent and metastatic CRC, demonstrating better response rate and higher disease control rate with acceptable tolerability, maintenance of QoL and convenient administration schedule. No significant financial relationships to disclose.
Morphological presentation of acute promyelocytic leukemia (APL) lacking the classical t(15;17) with special reference to a series of 9 cases with t(11;17)
Authors: D Sainty, Liso, A Cantu-Rajnoldi, D Head, MJ Mozziconacci, L Benattar, C Arnoulet, D Grimwade, A Biondi, F Birg, M Lafage-Pochitaloff, Anne hagemeijer-Hausman, G Flandrin
Journal: Blood (1998)
Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection
Authors: Joseph P Zackular, Jessica L Moore, Ashley T Jordan, Lillian J Juttukonda, Michael J Noto, Maribeth R Nicholson, Jonathan D Crews, Matthew W Semler, Yaofang Zhang, Lorraine B Ware, M Kay Washington, Walter J Chazin, Richard M Caprioli, Eric P Skaar
Journal: Nature Medicine (2016)
HHS Funds Development of Faster Zika Diagnostic Test
Authors: Jennifer Abbasi
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC).
Authors: Michael B. Atkins, F. Stephen Hodi, John A. Thompson, David F. McDermott, Wen-Jen Hwu, Donald P. Lawrence, Nancy Ann Dawson, Deborah Jean Lee Wong, Shailender Bhatia, Marihella James, Xinxin Shu, Rodolfo F. Perini, Nageatte Ibrahim, Antoni Ribas, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2016)

3013 Background: Pembro (anti–PD-1), ipi (anti–CTLA-4), and PEG-IFN (cytokine) are approved as monotherapy for treating melanoma. KEYNOTE-029 (NCT02089685) is a first-in-human, phase 1 study that includes independent pembro + ipi safety run-in and pembro + PEG-IFN dose-finding cohorts. Methods: Pts with advanced RCC with ≥ 1 prior therapy or melanoma with any number of prior therapies were eligible. Prior checkpoint therapy was not allowed. In the pembro + ipi safety run-in, pts received pembro 2 mg/kg Q3W + ipi 1 mg/kg Q3W for 4 doses, then pembro alone. Dose finding for pembro 2 mg/kg Q3W + PEG-IFN followed a toxicity probability interval-based design with 3-14 pts per dose level; the PEG-IFN dose was 1 μg/kg/wk at dose level (DL) 1 and 2 μg/kg/wk at DL2. Accrual continued until ≤ 4/14 pts at a given DL experienced a dose-limiting toxicity (DLT) during the first 6 wk. Response was assessed by RECIST v1.1 at wk 12, every 6 wk until wk 30, and every 12 wk thereafter. The data analysis cutoff date was Oct 26, 2015. Results: The pembro + ipi run-in cohort enrolled 12 pts with melanoma and 10 with RCC. After 13.8-mo median follow-up, 5 pts remained on pembro and 59% had ≥ 1 grade 3-4 drug-related AE. The PR and SD rates were 25% (n = 3) and 42% (n = 5) for melanoma and 30% (n = 3) and 30% (n = 3) for RCC. The pembro + PEG-IFN cohort enrolled 4 pts with melanoma and 10 with RCC. After a median 13.2 mo of follow-up, 3 pts remained on treatment. DLTs occurred in 1/11 pts (9%) at DL1 (grade 3 depression). At DL2, 2/3 pts (67%) had a DLT (1 grade 3 elevated AST, 1 grade 4 suicide attempt). Grade 3-4 drug-related AEs occurred in 57% of pts (55% at DL1, 67% at DL2), most commonly psychiatric disorders (21%). One pt (25%) with melanoma and 0 pts with RCC had PR; 2 pts (50%) with melanoma and 6 (60%) with RCC had SD. There were no drug-related deaths or unexpected AEs in either cohort. Conclusions: Pembro 2 mg/kg + ipi 1 mg/kg is tolerable and has promising antitumor activity in mostly heavily pretreated pts with advanced melanoma or RCC. This combination is being further evaluated in an ongoing melanoma expansion cohort. Pembro 2 mg/kg Q3W + PEG-IFN 1 μg/kg/wk is the maximum tolerated dose based on the DLT rate but appears to have limited antitumor activity. Clinical trial information: NCT02089685.
Simple, Less Expensive Psychotherapy Effective for Depression
Authors: Anita Slomski
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Extent of Resection and Survival in Glioblastoma Multiforme
Authors: Wafaa Jabbour, Didier Wion
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use
Authors: Lucas L van den Hoogen, Ruth D E Fritsch-Stork, Marjan A Versnel, Ronald H WM Derksen, Joël A G van Roon, Timothy R DJ Radstake
Journal: Annals of the Rheumatic Diseases (2016)

Several autoimmune diseases, most notably systemic lupus erythematosus (SLE), show an overexpression of type I interferon (IFN)-inducible genes, termed the IFN signature.1 The IFN signature is associated with endothelial progenitor cells (EPC) dysfunction in SLE2 and the recent report by Grenn et al 3 provides evidence for this link in antiphospholipid syndrome (APS) as well.

The authors show that patients with primary APS (PAPS) have a reduced number of circulating EPC that differentiate into endothelial cell like cells. This is supported by a similar reduction in EPC differentiation when EPC from healthy controls (HC) are cultured with serum from patients with PAPS. Whereas depletion of antiphospholipid antibodies (aPL) has no effect, blockade of the receptor for type I IFN restores EPC differentiation. Hence, targeting type I IFN might mitigate vascular disease in patients with APS by restoring EPC differentiation. In support of this assumption, the authors demonstrate the presence of an IFN signature in peripheral blood mononuclear cells (PBMC) of patients with PAPS.

Previous hints in the literature further confirm the presence of an IFN signature in PBMC of patients with PAPS.4 ,5 Interestingly, a microarray study on isolated monocytes of patients with SLE, SLE+APS and PAPS reported the presence of an IFN signature only in monocytes of patients with SLE and SLE+APS, not in PAPS.6 Monocytes are considered key players in the pathogenesis of APS4 among others due to an overexpression of tissue factor (TF), the main initiator of humoral coagulation, while shifts in monocyte subsets are linked to vascular disease in rheumatic diseases.7 ,8

Here we report the …
A Phase 1b Study of AMG 386 Plus Paclitaxel and Carboplatin in Ovarian Cancer Patients Undergoing Primary or Interval Debulking Surgery
Authors: I.B. Vergote, A. Oaknin Benzaquen, J. Baurain, S. Ananda, S. Wong, X. Yang, B. Wu, Z. Zhong, M. Puhlmann, A. Casado
Journal: Annals of Oncology (2012)
Bevacizumab, a vascular endothelial growth factor (VEGF) specific antibody reduces interstitial fluid pressure (IFP) in human rectal cancer xenograft (HT29) by day 5: Is this evidence for rescheduling its timing relative to chemotherapy?
Authors: M. Dani, B. Vojnovic, R. Newman, D. Honess, I. Wilson, I. Mitchell, R. Glynne-Jones
Journal: Journal of Clinical Oncology (2007)

4043 Background: Interstitial fluid pressure (IFP) of most solid tumours is increased relative to normal tissues; this is thought to be associated with the development of structurally and functionally abnormal blood and lymphatic vessels and interstitial fibrosis. Such interstitial hypertension creates a barrier for tumour transvascular transport, consequently compromising the delivery and efficacy of chemotherapy. We investigated the effect of Bevacizumab on IFP of a human rectal cancer xenograft. Methods: SCID mice bearing subcutaneous HT29 tumours of =8.5 mm diameter received a single dose of 10 mg/kg Bevacizumab intraperitoneally; controls received saline. Tumour IFP was measured in sedated mice (Hypnorm) on days 1, 3 and 5 post injection, using the wick-in-needle technique. Experiments were conducted under Home Office licence and approved by the local ethical committee. Results: Groups of 8 treated and control tumours were examined on days 1, 3 and 5 (n = 48). IFP was significantly lower (p&lt;0.0001) on day 5 in treated than control tumours (mean ± SD 15.1 ± 4.7 cf 36.9 ± 5.6 mm Hg). No significant differences (p&gt;0.05) between treated and control groups were seen on day 1 (31.8 ± 3.5 cf 30.6 ± 3.1 mm Hg) or day 3 (33.4 ± 5.5 cf 31.5 ± 3.2 mm Hg). No data were acquired on day 7 as the tumours ulcerated. Conclusions: Our data show that Bevacizumab causes a significant reduction of tumour IFP, but not until 5 days after treatment. Reduced IFP could augment uptake of cytotoxic drugs into tumour cells, hence timing of Bevacizumab relative to the first dose of chemotherapy could be of critical importance. No significant financial relationships to disclose.
A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment
Authors: Neeraj Gupta, Michael J Hanley, Karthik Venkatakrishnan, Raymond Perez, Robin E Norris, John Nemunaitis, Huyuan Yang, Gerald Falchook, Richard Labotka, Siqing Fu
Journal: Blood (2015)
Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera
Authors: Jie Bai, Limei Ai, Lei Zhang, Fengchun Yang, Yuan Zhou, Yanping Xue
Journal: American Journal of Hematology (2015)

Post-polycythemia vera myelofibrosis (post-PV MF) is a critical hematologic evolution of polycythemia vera (PV). The main purpose of the present study was to identify the possible risk factors for the occurrence and prognosis of post-PV MF in Chinese patients with PV. A cohort of 272 Chinese PV patients with JAK2V617F or exon12 mutation was retrospectively analyzed. Of the 272 patients with PV, 63 developed post-PV MF. Platelet count >550 × 109/L and splenomegaly were identified as independent risk factors for post-PV MF. The median duration of survival for post-PV MF patients was 8 years. Anemia and age >65 years at diagnosis of post-PV MF were identified as significant predictors for the poor prognosis of post-PV MF. In conclusion, platelet counts and splenomegaly were significant predictors for the transformation to post-PV MF, while anemia (hemoglobin levels <100 g/L) and age>65 years were significant predictors for poor prognosis of post-PV MF in Chinese PV patients with JAK2V617F or exon12 mutation. Am. J. Hematol. 90:1116–1121, 2015. © 2015 Wiley Periodicals, Inc.
The effect of combined therapy with 5-aza-2’-deoxycytidine, sodium butyrate, and tamoxifen on apoptosis of breast cancer cell lines.
Authors: S. J. Kim, J. S. Kim
Journal: Journal of Clinical Oncology (2011)

197 Background: DNA methytransferase inhibitors and histone deacetylase inhibitors have been extensively studied in recent years as another novel and specific target therapy for cancer treatment. In this study, we investigate the effect of combined therapy of 5-aza-2’-deoxycytidine (5-aza-CdR), sodium butyrate (SB) and tamoxifen on tumor suppression and expression of anti- or proapoptic proteins in breast cancer cell lines. Methods: Water-soluble tetrazolium salt-1 was used to study the proliferation rate of the cells in MDA-MB-231 and MCF-7 breast cell lines treated with the different concentration of variable combinations of these agents. Western blot was used to explore the change of expression of proapaptic regulator proteins according to variable combined therapy. Methylation specific transcriptase-polymerase chain reaction and immunofluorescence staining were used to analyze the ER re-expression in the MDA-MB-231 and MCF-7 cell lines treated with 5-aza-CdR. Results: We observed that the survival fraction of MCF-7 and MDA-MB-231 cells treated with 2um, 4um, 8um 5-aza-CdR and 0.5mM, 1mM and 2mM SB respectively was decreased in inverse proportion to the concentration. The survival fraction of MCF-7 cells as ER positive cell lines treated with 2.5um, 5um and 10um tamoxifen was slightly decreased in inverse proportion to the concentration, but that of MDA-MB-231 cells as ER negative cell lines was slightly increased regardless the concentration. ER re-expression was detected in ER negative cell line, MDA-MB-231 treated with 5-aza-CdR. In cases of being treated with variable combination of agents in MCF-7 and MDA-MB-231 cell lines, the survival fraction treated with the combination of all 5-aza-CdR, SB and tamoxifen was the lowest. We also observed that the expression of proapoptic regulator protein were slightly decreased in MCF-7 and MDA-MB-231 cells treated with combined 5-aza-CdR with SB and combined with all agents. Conclusions: Our data indicate that combined therapy with 5-aza-CdR, SB and tamoxifen was the most effective in apoptosis of breast cancer cells and changed expression of the proapoptic regulator proteins.
Addressing Social Determinants of Health and Health Inequalities
Authors: Nancy E. Adler, M. Maria Glymour, Jonathan Fielding
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The relation between post-systolic shortening and residual viable myocardium after acute myocardial infarction: A comparison of strain rate imaging with magnetic resonance tomography and scintigraphy
Authors: Jens-Uwe Voigt, M Regenfus, G Lindenmeier, C Schlundt, U Nixdorff, FA Flachskampf, WG Daniel
Journal: Journal of the American College of Cardiology (2001)
Eliminating Unnecessary Processes in Primary Care
Authors: Adam J. Schoenfeld, Patrick G. O’Malley
Journal: JAMA Internal Medicine (2016)

able Care Act were crafted to shed light on physician and hospital interactions with industry.However, a critical gap is that it does not capture payments made to other health care professionals that may also influence, both directly or indirectly, purchasing decisions that are made for pharmaceuticals or medical devices.Senators Chuck Grassley (R-Iowa) and Richard Blumenthal (D-Connecticut) have recently introduced the Provider Payment Sunshine Act (S. 2153) that would partially expand the Sunshine provisions to include other prescribing professionals, eg, nurse practitioners and physician assistants. 9 Based on Grundy's study, and what is revealed by the Massachusetts data, it is clear that even the Provider Payment Sunshine Act does not go far enough.All nurses, in addition to the myriad of professionals that are included in the Massachusetts reporting regulations, should be covered under the Provider Payment Sunshine Act or related legislation.In the United States, the pharmaceutical and medical device industries have fashioned a remarkable web of influence with strands that capture more than just the obvious players-that is, physicians.This web reaches a wide cadre of health care professions and risks accumulating conflicts of interest into every corner of our health care system.However, without inclusion in transparency policies and reporting mechanisms, it is difficult if not impossible to say what influence industry has on nurses and other health care professionals.One can assume it is at least worth the cost of a dinner.